Breast Cancer Biologics: A Comprehensive Market Analysis of Trastuzumab Biosimilars
Breast cancer remains a leading cause of cancer-related deaths among women worldwide, with HER2-positive subtypes accounting for a significant portion of cases. The introduction of trastuzumab, a targeted biologic, revolutionized the treatment of this aggressive cancer. The subsequent development of breast cancer biologics in the form of trastuzumab biosimilars has expanded access to...
0 Commentarii 0 Distribuiri 119 Views 0 previzualizare